JP2010509369A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010509369A5 JP2010509369A5 JP2009536520A JP2009536520A JP2010509369A5 JP 2010509369 A5 JP2010509369 A5 JP 2010509369A5 JP 2009536520 A JP2009536520 A JP 2009536520A JP 2009536520 A JP2009536520 A JP 2009536520A JP 2010509369 A5 JP2010509369 A5 JP 2010509369A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- vegf
- antibody
- use according
- average thickness
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000005557 antagonist Substances 0.000 claims description 17
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 16
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 16
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 12
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 12
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 238000005259 measurement Methods 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 229960003876 ranibizumab Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 14
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86538006P | 2006-11-10 | 2006-11-10 | |
| PCT/US2007/084320 WO2008063932A2 (en) | 2006-11-10 | 2007-11-09 | Method for treating age-related macular degeneration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010509369A JP2010509369A (ja) | 2010-03-25 |
| JP2010509369A5 true JP2010509369A5 (OSRAM) | 2010-12-02 |
Family
ID=39323041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009536520A Pending JP2010509369A (ja) | 2006-11-10 | 2007-11-09 | 加齢黄斑変性症を処置するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20100111963A1 (OSRAM) |
| EP (1) | EP2089059A2 (OSRAM) |
| JP (1) | JP2010509369A (OSRAM) |
| AU (1) | AU2007323925A1 (OSRAM) |
| CA (1) | CA2666709A1 (OSRAM) |
| WO (1) | WO2008063932A2 (OSRAM) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ590132A (en) * | 2004-10-21 | 2012-03-30 | Genentech Inc | Dosage regime for treating intraocular neovascular diseases with VEGF |
| CN110372792A (zh) | 2008-06-25 | 2019-10-25 | 艾斯巴技术-诺华有限责任公司 | 抑制vegf的稳定和可溶的抗体 |
| LT3444274T (lt) | 2008-06-25 | 2021-03-25 | Novartis Ag | Stabilūs ir tirpūs antikūnai, slopinantys tnf |
| US20110200612A1 (en) * | 2008-06-30 | 2011-08-18 | Michael Schuster | Treatment of eye diseases and excessive neovascularization using combined therapy |
| US8821870B2 (en) | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
| JP5606438B2 (ja) | 2008-07-23 | 2014-10-15 | エフ．ホフマン−ラ ロシュ アーゲー | 抗血管新生療法を受容可能な被験体の同定 |
| DK2524693T3 (da) * | 2010-01-14 | 2014-08-25 | Sanwa Kagaku Kenkyusho Co | Lægemiddel til forebyggelse eller behandling af lidelser ledsaget af okulær angiogenese og / eller forøget okulær vaskulær permeabilitet |
| AR083495A1 (es) | 2010-10-22 | 2013-02-27 | Esbatech Alcon Biomed Res Unit | Anticuerpos estables y solubles |
| JP5934229B2 (ja) * | 2010-10-27 | 2016-06-15 | ノバルティス アーゲー | 眼血管疾患の処置のための投与計画 |
| BR112013017752A8 (pt) | 2011-01-13 | 2018-01-09 | Regeneron Pharma | uso de um antagonista do vegf e formulação farmacêutica |
| WO2012105610A1 (ja) * | 2011-02-02 | 2012-08-09 | 公立大学法人名古屋市立大学 | 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬 |
| US11458199B2 (en) * | 2012-08-21 | 2022-10-04 | Opko Pharmaceuticals, Llc | Liposome formulations |
| MX363822B (es) * | 2012-08-21 | 2019-04-04 | Opko Pharmaceuticals Llc | Formulaciones de liposomas. |
| EP3003343B1 (en) * | 2013-06-07 | 2019-10-23 | The Johns Hopkins University | A biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases |
| KR20160058835A (ko) * | 2013-10-08 | 2016-05-25 | 에프. 호프만-라 로슈 아게 | 안질환 치료를 위한 n-(4-3차-부틸-벤질)-3-클로로-n-[2-(4-클로로-3-에틸-페닐)-에틸]-2-플루오로-5-트라이플루오로메틸-벤즈-아미드의 용도 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| JP6835836B2 (ja) * | 2015-10-13 | 2021-02-24 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 脈絡膜血管新生の処置のための方法及び医薬組成物 |
| KR101880670B1 (ko) * | 2015-11-06 | 2018-08-16 | 주식회사 모다이노칩 | 압력 센서를 구비하는 전자기기 |
| CA3007276C (en) | 2015-12-03 | 2021-12-28 | Regeneron Pharmaceuticals, Inc. | Use of vegf inhibitor to treat macular degeneration in a patient population |
| AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| US20190231986A1 (en) * | 2016-09-19 | 2019-08-01 | Lupin Limited | In-Line Filter For Protein/Peptide Drug Administration |
| EP3716992B1 (en) | 2017-11-30 | 2022-08-10 | Regeneron Pharmaceuticals, Inc. | Use of a vegf antagonist to treat angiogenic eye disorders |
| CA3089952A1 (en) | 2018-02-02 | 2019-08-08 | Kyoto University | Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability |
| CN112203679A (zh) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
| WO2020109343A1 (en) | 2018-11-29 | 2020-06-04 | F. Hoffmann-La Roche Ag | Combination therapy for treatment of macular degeneration |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US190317A (en) * | 1877-05-01 | Improvement in barbers chairs | ||
| US6582959B2 (en) * | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| US6703020B1 (en) * | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| US7306799B2 (en) * | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
| BR0307548A (pt) * | 2002-02-11 | 2006-01-17 | Genentech Inc | Método de produção de uma variante de anticorpo, variante de anticorpo, composição, ácido nucléico isolado, vetor, célula hospedeira, processo para a produção de uma variante de anticorpo e método de determinação do coeficiente de associação de antìgeno de um anticorpo |
-
2007
- 2007-11-09 WO PCT/US2007/084320 patent/WO2008063932A2/en not_active Ceased
- 2007-11-09 US US12/514,445 patent/US20100111963A1/en not_active Abandoned
- 2007-11-09 CA CA002666709A patent/CA2666709A1/en not_active Abandoned
- 2007-11-09 EP EP07871431A patent/EP2089059A2/en not_active Withdrawn
- 2007-11-09 AU AU2007323925A patent/AU2007323925A1/en not_active Abandoned
- 2007-11-09 JP JP2009536520A patent/JP2010509369A/ja active Pending
-
2011
- 2011-09-19 US US13/236,515 patent/US20120009185A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010509369A5 (OSRAM) | ||
| JP2022031772A5 (OSRAM) | ||
| JP2014506321A5 (OSRAM) | ||
| JP2017534638A5 (OSRAM) | ||
| NZ598502A (en) | Use of vegf antagonists in intraocular neovascular disease treatment | |
| JP2016520573A5 (OSRAM) | ||
| NZ592039A (en) | Combination therapy for the treatment of ocular neovascular disorders | |
| JP2017528483A5 (OSRAM) | ||
| JP2017535547A5 (OSRAM) | ||
| WO2006015775A3 (en) | Egfr kinase inhibitor combinations for treating respiratory and gastrointestinal disorders | |
| WO2017031319A1 (en) | Noradrenergic drug treatment of obstructive sleep apnea | |
| CN106999511A (zh) | 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗 | |
| JP2012502103A5 (OSRAM) | ||
| RU2010107843A (ru) | Бупропиона гидробромид и его терапевтические применения | |
| JP2014503593A5 (OSRAM) | ||
| JP2022041802A5 (OSRAM) | ||
| JP2012522788A5 (OSRAM) | ||
| JP2018530574A5 (OSRAM) | ||
| JP2017523974A5 (OSRAM) | ||
| EP3735237A1 (en) | Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere's disease, tourette's syndrome, attention deficit hyperactivity disorder and addiction | |
| Singh et al. | Pharmacological treatment of COPD: the devil is always in the detail | |
| JP2015522077A5 (OSRAM) | ||
| Custodio et al. | Lack of clinically relevant effect of bictegravir (BIC, B) on metformin (MET) pharmacokinetics (PK) and pharmacodynamics (PD) | |
| JP2017520562A5 (OSRAM) | ||
| JP2013536206A5 (OSRAM) |